Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

FDA Grants Orphan-Drug Designation for Hemophilia Gene Therapy

December 30, 2021

The FDA granted orphan-drug designation to the adeno-associated virus stereotype vector SHP654 (also known as BAX 888), an investigational factor VIII (FVIII) gene therapy for the treatment of hemophilia A. The investigational therapy is intended to provide a long-acting, constant level of factor expression over several years and eliminate the need for factor-replacement therapy. A phase I/II study of SHP654 is expected to begin in the late 2017.

Source: Shire press release, October 25, 2017.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
October 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals